𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma

✍ Scribed by Susan Huan; Richard Pazdur; Amnuay Singhakowinta; Bohumil Samal; Vainutis K. Vaitkevicus


Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
363 KB
Volume
63
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Evaluation of low dose continuous infusi
✍ Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Buesche πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 289 KB πŸ‘ 2 views

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology

Bimonthly high dose leucovorin and 5-flu
✍ Karine Beerblock; Yves Rinaldi; Thierry AndrΓ©; Christophe Louvet; Eric Raymond; πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 86 KB πŸ‘ 1 views

with low dose LV. Based on these reports, a first-line Phase II study was performed in 101 patients with advanced colorectal carcinoma who were given a bimonthly

Continuous infusion of 5-fluorouracil an
✍ Yong-Suk Chung; Yoshito Yamashita; Tohru Inoue; Tasuku Matsuoka; Bunzo Nakata; N πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 85 KB πŸ‘ 1 views

City Uni-11 cases, for an overall response rate of 50%. Patients with good performance versity Medical School, Osaka, Japan. status (PS) (0-1) and differentiated histologic type showed higher response rates (50.0% and 63.6%, respectively) than patients with poor PS (2 or 3) and undifferenti-2 Insti

Palliative treatment with low-dose conti
✍ Abderrahim Fandi; Abdelkrim Taamma; Nacer Azli; Mounir Bachouchi; Bashar Yanes; πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 59 KB πŸ‘ 1 views

## Background: Low-dose protracted continuous infusion (ci) 5-fluorouracil (5-fu), as proposed by lokich et al, has been reported to be active and well tolerated in colorectal and breast cancers. we initiated a phase ii trial with ci 5-fu in heavily pretreated undifferentiated carcinoma of the naso